INSIDE INFORMATION Combination of ATO with copper salts will allow BioSenic to work towards reducing the dosage of ATO in future trials overall and maintain efficacy Mont-Saint-Guibert,. | March 30, 2023
BIOSENIC Euronext Brussels and Paris: BIOS), the company specialized in serious autoimmune inflammatory diseases and cell repair, today announces an update on its systemic autoimmune disease. | November 9, 2022
Bone Therapeutics to broaden and derisk therapeutic portfolio by acquiring majority participation in Medsenic The acquisition will result in the business combination of Bone Therapeutics and Medsenic to create BioSenic, a speciality biopharma company51 percent of Medsenic shares (valued at ca EUR 40 million) to.